{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:21:16Z","timestamp":1777317676860,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Few studies explore the burden of mild-to-moderate atopic dermatitis (AD). We aimed to investigate disease burden in mild-to-moderate AD using real-world data from adults with AD and their physicians in the United States. Data were drawn from the Adelphi Real World AD Disease Specific Programme\u2122, a cross-sectional survey of physicians and their patients with AD in real-world clinical practice in the US from November 2014 to February 2015. Physicians provided data for the next five eligible adults who consulted the physician. Patients had a physician-reported history of moderate-to-severe AD. Overall, 284 and 554 adults with physician-perceived mild or moderate AD at the most recent consultation, respectively, were included in the analysis. Patients with moderate AD experienced more flares (<jats:italic>p<\/jats:italic>\u2009&lt;.001) and had dry skin, pruritus, and cracking\/raw skin day-to-day that were more severe (<jats:italic>p<\/jats:italic>\u2009&lt;.0001) and when experiencing a flare (<jats:italic>p<\/jats:italic>\u2009&lt;.05) than patients with mild AD. Adults with either mild or moderate AD used a similar number of treatments. Patients with moderate AD reported greater impact on health status, health-related quality of life, and productivity than those with mild AD. Adults with mild-to-moderate AD experienced substantial daily impact from symptoms despite multiple therapies. Unmet needs remain and more can be done to improve disease control in adults with mild-to-moderate AD.<\/jats:p>","DOI":"10.1007\/s00403-025-03910-y","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:46:58Z","timestamp":1741783618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States"],"prefix":"10.1007","volume":"317","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Levenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela E.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"2","key":"3910_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3122\/jabfm.2019.02.180225","volume":"32","author":"J Al-Naqeeb","year":"2019","unstructured":"Al-Naqeeb J, Danner S, Fagnan LJ et al (2019) The burden of childhood atopic dermatitis in the primary care setting: a report from the Meta-LARC Consortium. J Am Board Fam Med 32(2):191\u2013200","journal-title":"J Am Board Fam Med"},{"issue":"11","key":"3910_CR2","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J (2008) Real-world physician and patient behaviour across countries: Disease-Specific programmes - a means to understand. Curr Med Res Opin 24(11):3063\u20133072","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"3910_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399\u2013424","journal-title":"Multivar Behav Res"},{"issue":"8 Suppl","key":"3910_CR4","first-page":"S115","volume":"23","author":"C Avena-Woods","year":"2017","unstructured":"Avena-Woods C (2017) Overview of atopic dermatitis. Am J Manag Care 23(8 Suppl):S115\u2013s23","journal-title":"Am J Manag Care"},{"issue":"4","key":"3910_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/j.1541-0420.2005.00377.x","volume":"61","author":"H Bang","year":"2005","unstructured":"Bang H, Robins JM (2005) Doubly robust estimation in missing data and causal inference models. Biometrics 61(4):962\u2013973","journal-title":"Biometrics"},{"issue":"6","key":"3910_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A et al (2018) Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 73(6):1284\u20131293","journal-title":"Allergy"},{"issue":"2","key":"3910_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","volume":"22","author":"T Bieber","year":"2010","unstructured":"Bieber T (2010) Atopic dermatitis. Ann Dermatol 22(2):125\u2013137","journal-title":"Ann Dermatol"},{"key":"3910_CR8","doi-asserted-by":"crossref","unstructured":"Boguniewicz M, Alexis A, Beck L et al (2017) Expert perspectives on Management of Moderate-to-severe atopic dermatitis: a Multidisciplinary Consensus addressing current and emerging therapies. The journal of allergy and clinical immunology in practice. 5(6):1519\u20131531","DOI":"10.1016\/j.jaip.2017.08.005"},{"issue":"1","key":"3910_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","volume":"137","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, Silverberg JI, Guttman-Yassky E et al (2017) Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol 137(1):18\u201325","journal-title":"J Invest Dermatol"},{"issue":"12","key":"3910_CR10","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC (2004) The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol 140(12):1513\u20131519","journal-title":"Arch Dermatol"},{"issue":"3","key":"3910_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M et al (2019) Atopic dermatitis in America Study: a cross-sectional study examining the prevalence and Disease Burden of atopic dermatitis in the US Adult Population. J Invest Dermatol 139(3):583\u2013590","journal-title":"J Invest Dermatol"},{"issue":"4","key":"3910_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1159\/000519361","volume":"238","author":"A Chiricozzi","year":"2022","unstructured":"Chiricozzi A, Gori N, Di Nardo L et al (2022) Therapeutic impact and management of Persistent Head and Neck atopic dermatitis in Dupilumab-treated patients. Dermatology 238(4):717\u2013724","journal-title":"Dermatology"},{"issue":"5","key":"3910_CR13","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.15641","volume":"177","author":"R Chopra","year":"2017","unstructured":"Chopra R, Vakharia PP, Sacotte R et al (2017) Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 177(5):1316\u20131321","journal-title":"Br J Dermatol"},{"issue":"1","key":"3910_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/biomet\/asn055","volume":"96","author":"RK Crump","year":"2009","unstructured":"Crump RK, Hotz VJ, Imbens GW, Mitnik OA (2009) Dealing with limited overlap in estimation of average treatment effects. Biometrika 96(1):187\u2013199","journal-title":"Biometrika"},{"issue":"9","key":"3910_CR15","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"L DeTora","year":"2022","unstructured":"DeTora L, Toroser D, Sykes A et al (2022) Good publication practice (GPP) guidelines for Company-Sponsored Biomedical Research: 2022 update. Ann Intern Med 175(9):1298\u20131304","journal-title":"Ann Intern Med"},{"issue":"1","key":"3910_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ et al (2017) The burden of atopic dermatitis: Summary of a report for the National Eczema Association. J Invest Dermatol 137(1):26\u201330","journal-title":"J Invest Dermatol"},{"issue":"1","key":"3910_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaad.2017.08.002","volume":"78","author":"L Eckert","year":"2018","unstructured":"Eckert L, Gupta S, Amand C et al (2018) The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol 78(1):54\u201361e1","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3910_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2017.04.019","volume":"77","author":"L Eckert","year":"2017","unstructured":"Eckert L, Gupta S, Amand C et al (2017) Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol 77(2):274\u20139e3","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3910_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Chamlin SL et al (2014) Guidelines of care for the management of atopic dermatitis: Sect.\u00a01. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 70(2):338\u2013351","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3910_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210\u2013216","journal-title":"Clin Exp Dermatol"},{"key":"3910_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","volume":"14","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P et al (2024) Management of patients affected by moderate-to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: an Italian Delphi Consensus. Dermatol Ther 14:919\u2013932","journal-title":"Dermatol Ther"},{"issue":"5","key":"3910_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"Y Leshem","year":"2015","unstructured":"Leshem Y, Hajar T, Hanifin J, Simpson E (2015) What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 172(5):1353\u20131357","journal-title":"Br J Dermatol"},{"issue":"2","key":"3910_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.anai.2019.05.014","volume":"123","author":"C McKenzie","year":"2019","unstructured":"McKenzie C, Silverberg JI (2019) The prevalence and persistence of atopic dermatitis in urban United States children. Ann Allergy Asthma Immunol 123(2):173\u20138e1","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"3910_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33(5):337\u2013343","journal-title":"Ann Med"},{"issue":"5","key":"3910_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2165\/00044011-199611050-00004","volume":"11","author":"MC Reilly","year":"1996","unstructured":"Reilly MC, Tanner A, Meltzer EO (1996) Work, classroom and activity impairment instruments. Clin Drug Investig 11(5):278\u2013288","journal-title":"Clin Drug Investig"},{"issue":"398","key":"3910_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","volume":"82","author":"PR Rosenbaum","year":"1987","unstructured":"Rosenbaum PR (1987) Model-based direct adjustment. J Am Stat Assoc 82(398):387\u2013394","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"3910_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.det.2017.02.004","volume":"35","author":"C Sibbald","year":"2017","unstructured":"Sibbald C, Drucker AM (2017) Patient burden of atopic dermatitis. Dermatol Clin 35(3):303\u2013316","journal-title":"Dermatol Clin"},{"issue":"4","key":"3910_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A et al (2021) Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol 126(4):417\u201328e2","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3910_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/jid.2014.325","volume":"135","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC (2015) Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol 135(1):56\u201366","journal-title":"J Invest Dermatol"},{"key":"3910_CR30","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ et al (2019) Health Utility scores of atopic dermatitis in US adults. The journal of allergy and clinical immunology in practice. 7(4):1246\u201352e1","DOI":"10.1016\/j.jaip.2018.11.043"},{"issue":"5","key":"3910_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ et al (2018) Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol 121(5):604\u2013612 e3","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"3910_CR32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ et al (2018) Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol 121(3):340\u2013347","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3910_CR33","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Gruben D, Smith TW, Fung S, Myers DE (eds) (2020) The economic burden of mild-to-moderate atopic dermatitis in the United States: Analyses of the National Health and Wellness Survey. Revolutionizing Atopic Dermatitis (RAD) Virtual Conference; Chicago, IL","DOI":"10.1016\/j.jaad.2020.06.383"},{"issue":"5","key":"3910_CR34","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","volume":"132","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Hanifin JM (2013) Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 132(5):1132\u20131138","journal-title":"J Allergy Clin Immunol"},{"key":"3910_CR35","unstructured":"Szende A, Oppe M, Devlin N (2007) EQ-5D value sets: Inventory, comparative review and user guide. Dordrecht, Netherlands.ISBN-10 1-4020-5510-2 (HB) ISBN-13 978-1-4020-5510-2 (HB) ISBN-10 1-4020-5511-0 (e-book) ISBN-13 978-1-4020-5511-9 (e-book) p"},{"issue":"6","key":"3910_CR36","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.anai.2017.09.076","volume":"119","author":"PP Vakharia","year":"2017","unstructured":"Vakharia PP, Chopra R, Sacotte R et al (2017) Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol 119(6):548\u2013552 e3","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"3910_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh S, Larsen H et al (2023) A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol 37(5):1046\u20131055","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3910_CR38","doi-asserted-by":"crossref","unstructured":"Yu SH, Attarian H, Zee P, Silverberg JI (2016) Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis: contact, atopic, occupational, drug. 27(2):50\u2013\u20098","DOI":"10.1097\/DER.0000000000000161"},{"issue":"1","key":"3910_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jaci.2006.02.031","volume":"118","author":"T Zuberbier","year":"2006","unstructured":"Zuberbier T, Orlow SJ, Paller AS et al (2006) Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 118(1):226\u2013232","journal-title":"J Allergy Clin Immunol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03910-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-03910-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03910-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:47:05Z","timestamp":1741783625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-03910-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3910"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-03910-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the ICC\/ESOMAR International Code on Market, Opinion and Social Research and Analytics (). Ethical approval was not attained because this was a real-world non-interventional study. Instructions described the survey\u2019s purpose, why respondents were selected, and who might have access to the aggregated and anonymized datasets.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Before patients could volunteer to complete a questionnaire, they were asked to provide informed consent. Using a checkbox, patients provided informed consent to take part in the survey. Data were collected in such a way that patients and physicians could not be identified directly.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"Jonathan Silverberg has received honoraria or consultant fees for Pfizer Inc., AbbVie, Aldena Therapeutics, Amgen, AOBiome LLC, Arcutis Inc, Arena Pharmaceuticals, Asana Biosciences LLC, ASLAN Pharmaceuticals, BiomX Inc, Biosion, Bodewell, Boehringer Ingelheim, Cara Therapeutics, Castle Biosciences, Celegene, Connect Biopharma LLC, Corrona Inc, Dermavant Sciences, Eli Lilly and Company, Galderma Research & Development LLC, GlaxoSmithKline, Incyte Corporation, LEO Pharma Inc, Optum, Novartis, RAPT Therapeutics, Regeneron, Sanofi, Shaperon, TARGET Pharma, and Union Therapeutics; has served as a speaker for Pfizer Inc., AbbVie, Eli Lilly and Company, Incyte Corporation, LEO Pharma, Maui Derm, Regeneron, and Sanofi Genzyme; and served as an investigator for AbbVie, Eli Lilly and Company, GlaxoSmithKline, Kiniksa Pharmaceutics Ltd, Optum, Regeneron, and TARGET Pharma. Peter Anderson, and James Piercy are employees of Adelphi Real World, a company that received research funding from Pfizer Inc. Daniela E. Myers, Mark E. Levenberg, and Joseph C. Cappelleri are employees and stockholders of Pfizer Inc., which supported this study. Robert A. Gerber was an employee and stockholder of Pfizer Inc at the time this research was conducted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"556"}}